Middeldorp S

No ORCID on file · 5 papers in corpus · active 2016-2024
2024
Heavy menstrual bleeding on direct factor Xa inhibitors: the MEDEA randomized clinical trial.
Research and practice in thrombosis and haemostasis ·doi:10.1016/j.rpth.2024.102448
2024
Hormone-related thrombosis: duration of anticoagulation, risk of recurrence, and the role of hypercoagulability testing.
Hematology. American Society of Hematology. Education Program ·doi:10.1182/hematology.2024000593

Hormone-related venous thromboembolism (VTE) is common and entails scenarios in which VTE occurs during exposure to exogenous or endogenous female sex hormones, typically estrogen and progestogen. For the management of hormone-related VTE, …

2020
Women's health in The BMJ: a data science history.
BMJ open ·doi:10.1136/bmjopen-2020-039759

ObjectiveTo determine how the representation of women's health has changed in clinical studies over the course of 70 years.DesignObservational study of 71 866 research articles published between 1948 and 2018 in The BMJ.Main outcome measure…

2018
Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study.
BJOG : an international journal of obstetrics and gynaecology ·doi:10.1111/1471-0528.15388

ObjectiveTo investigate the characteristics and outcome of abnormal vaginal bleeding in women receiving edoxaban or warfarin for treatment of venous thromboembolism (VTE).Design and settingPost hoc analysis of the Hokusai-VTE study, a multi…

2016
Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use.
Blood ·doi:10.1182/blood-2015-08-665927

Women receiving vitamin K antagonists (VKAs) require adequate contraception because of the potential for fetal complications. It is unknown whether the use of hormonal therapy, especially those containing estrogens, is associated with recur…